Walker Neal 4

What Happened

• Walker Neal, CEO and Director of Aclaris Therapeutics (ACRS), was granted two restricted stock unit (RSU) awards on Feb 2, 2026: 274,800 RSUs and 961,700 RSUs, for a total of 1,236,500 RSUs. The grants are recorded at $0.00 per unit on the Form 4 (derivative awards), meaning no cash changed hands at grant.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 6, 2026 (appears to be filed after the typical 2-business-day window).
• Grant amounts: 274,800 RSUs and 961,700 RSUs (total 1,236,500 RSUs); price reported: $0.00 per unit.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes from the filing:
  • F1: Each RSU represents a contingent right to receive one share of common stock.
  • F2: These RSUs vest in four equal installments on the 1st, 2nd, 3rd and 4th anniversaries of Feb 2, 2026, subject to continuous service.
  • F3: The filing also describes a standard option vesting pattern (25% at first anniversary, then equal installments annually) — relevant if options were part of other awards.
• Filing timeliness: The Form 4 was filed four days after the transaction date, which appears later than the usual two-business-day filing requirement.

Context

• These are compensation awards (RSUs), not open-market purchases or sales. RSUs give the holder a future right to shares if vesting conditions are met and generally do not result in immediate proceeds or share sales. Such awards are common executive compensation; they increase potential future share holdings if vested but do not by themselves indicate a buy/sell decision in the market.